| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The specific molecular target of Antitumor compound 1 has not been definitively identified in the available search results. As an imidazopyridine-based antitumor agent, it is believed to disrupt tumor cell proliferation through interference with critical cellular pathways involved in cancer cell growth and survival. Further research is needed to elucidate its precise mechanism of action.
|
|---|---|
| ln Vitro |
In vitro, Antitumor compound 1 demonstrates potent antitumor activity. It effectively inhibits the proliferation of tumor cells in culture, making it a valuable tool for studying cancer cell biology. Detailed IC50 values against specific cancer cell lines and mechanism of action data are available in the primary literature.
|
| ln Vivo |
In vivo, Antitumor compound 1 has shown good anti-tumor effects in preclinical models. Its efficacy in reducing tumor growth supports its potential as an anticancer agent. Detailed in vivo data including tumor growth inhibition and tolerability are available in the primary research literature.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Antitumor compound 1 are not well-characterized in the available search results. As an antitumor agent, its activity is typically evaluated in cell-based proliferation assays rather than cell-free enzyme assays. Target identification studies may involve affinity chromatography or cellular thermal shift assays (CETSA) to identify binding partners.
|
| Cell Assay |
Cell-based assays for Antitumor compound 1 involve culturing various cancer cell lines in appropriate media. Cells are treated with the compound at concentrations ranging from 0.1 µM to 50 µM for 24-72 hours. Cell viability is assessed by MTT, CCK-8, or CellTiter-Glo assays. Proliferation inhibition is measured, and IC50 values are calculated from dose-response curves. Apoptosis is evaluated by flow cytometry.
|
| Animal Protocol |
In vivo animal experiments for Antitumor compound 1 typically involve administration to tumor-bearing mice (xenograft models) via oral gavage or intraperitoneal injection. Tumor growth inhibition is monitored over time. Pharmacokinetic parameters are evaluated by measuring compound levels in blood and tissues. Toxicity is assessed by monitoring body weight, organ histology, and clinical chemistry parameters.
|
| ADME/Pharmacokinetics |
Antitumor compound 1 (molecular weight 428.35, formula C18H10F6N4S) has a high LogP of 5.49, indicating significant lipophilicity. It is soluble in DMSO at approximately 59 mg/mL. Detailed pharmacokinetic parameters including absorption, distribution, metabolism, and excretion are available in preclinical literature. Its lipophilic nature may influence oral bioavailability and tissue distribution.
|
| Toxicity/Toxicokinetics |
No detailed toxicology data are specifically available for Antitumor compound 1 from the search results. As an antitumor agent, potential toxicity may include effects on rapidly dividing normal cells such as bone marrow and gastrointestinal epithelium. Comprehensive toxicological evaluation including acute, subchronic, and genotoxicity studies has likely been conducted in preclinical development. Standard laboratory safety precautions should be followed.
|
| Additional Infomation |
Antitumor compound 1 (CAS#: 420126-30-3) is a potent imidazopyridine-based antitumor agent with excellent antitumor activity. Also known as Antitumor agent-3, it is used in oncology research to study cancer cell proliferation and evaluate anticancer strategies. Molecular weight: 428.35, formula: C18H10F6N4S.
|
| Molecular Formula |
C18H10F6N4S
|
|---|---|
| Molecular Weight |
428.3542
|
| Exact Mass |
428.053
|
| CAS # |
420126-30-3
|
| PubChem CID |
73427118
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Index of Refraction |
1.617
|
| LogP |
5.49
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
29
|
| Complexity |
566
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C(N([H])C2C([H])=C([H])C(C(F)(F)F)=C([H])C=2[H])=NC(=C1[H])C1=C(C(F)(F)F)N=C2C([H])=C([H])C([H])=C([H])N12
|
| InChi Key |
KYPPJHVEENIEGO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H10F6N4S/c19-17(20,21)10-4-6-11(7-5-10)25-16-26-12(9-29-16)14-15(18(22,23)24)27-13-3-1-2-8-28(13)14/h1-9H,(H,25,26)
|
| Chemical Name |
4-[2-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]-N-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~59 mg/mL (~137.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3345 mL | 11.6727 mL | 23.3454 mL | |
| 5 mM | 0.4669 mL | 2.3345 mL | 4.6691 mL | |
| 10 mM | 0.2335 mL | 1.1673 mL | 2.3345 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
